Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects (CHEER)
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party)
First received: September 12, 2007
Last updated: July 10, 2018
Last Verified: July 2018
History of Changes
The primary objective of this study is:
To assess the virologic effect of changing enfuvirtide to MK-0518(raltegravir) in human immunodeficiency virus type 1(HIV-1) infected patients who have an undetectable level of serum human immunodeficiency virus(HIV) (< 75 copies/ml by branch deoxyribonucleic acid (bDNA) assay, < 50 copies/ml by Ultrasensitive Polymerase Chain Reaction(PCR) assay) on their current HIV medication regimen.
HIV-1 infected individuals well controlled on an enfuvirtide containing regimen with HIV RNA levels below limits of quantification can safely have the investigational integrase inhibitor, MK-0518 substituted for enfuvirtide without loss of virologic suppression.
Drug : raltegravir
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen|
Further study details as provided by Kaiser Permanente:
Primary Outcome Measures
Number of Patients With Undetectable Human Immunodeficiency Virus (HIV) Viral Load at Week 24.
[ Time Frame: 24 Weeks ]
To assess the virologic effect of changing enfuvirtide to MK-0518 (raltegravir) in human immunodeficiency virus type 1 (HIV-1) infected patients who have an undetectable level of serum HIV (undetectable level of serum HIV defined as < 75 copies/ml by bDNA assay or < 50 copies/ml by Ultrasensitive PCR assay) on their current HIV medication regimen.
- Average Change in Cluster of Differentiation 4(CD4) Cell Count From Baseline at Week 24
[ Time Frame: 24 Weeks ]
To study the immunologic effect of changing enfuvirtide to MK-0518 (raltegravir) in HIV-1 infected patients who have an undetectable level of serum HIV (undetectable serum HIV defined as < 75 copies/ml by bDNA assay or < 50 copies/ml by Ultrasensitive PCR assay)on their current HIV medication regimen.
|Study Start Date:||September 2007|
|Study Completion Date:||September 2009|
|Primary Completion Date:||July 2008 (Final data collection date for primary outcome measure)|
Open label, single arm. All patients to receive MK-0518 400mg orally twice a day for 24 weeks, as substitution for enfuvirtide.
This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
Other Name: MK-0518, Isentress
Human immunodeficiency virus type 1(HIV-1) infected patients who have had an undetectable viral load on an enfuvirtide containing regimen at the Kaiser Permanente Hayward, Los Angeles, San Francisco, and Santa Clara Medical Centers will be enrolled. Patients will receive open label MK-0518 (raltegravir) 400mg orally twice a day as substitution for enfuvirtide for 24 weeks.Eligibility
|Ages Eligible for Study:||18 Years and older|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients must meet all of the following inclusion criteria to be eligible for
participation in this study.
- Subject is ≥ 18 years of age and able to understand and willing to sign a written informed consent form, which must be obtained prior to initiation of the study.
- Documented laboratory diagnosis of HIV-1 infection (positive Enzyme-linked immunosorbent assay (ELISA) HIV-1 antibody test confirmed by western blot, p24 assay, HIV-1 RNA, or culture).
- Have documented plasma HIV-1 RNA level(s) of < 75 copies/ml by branched deoxyribonucleic acid(bDNA) assay, or < 50 copies/ml by Ultrasensitive Polymerase Chain Reaction(PCR) for at least 6 months prior to screening visit.
- Currently receiving a stable antiretroviral regimen consisting of enfuvirtide plus at least 2 other antiretrovirals for at least 6 months.
- Negative serum pregnancy test (females of childbearing potential only) and are willing to use an adequate method of contraception throughout the duration of the study.
- Exclusion Criteria:
- Patients who meet any of the following exclusion criteria are not to be enrolled in
- Any prior therapy with MK-0518 or any other HIV-1 integrase inhibitor.
- Any HIV-1 viral load > 75 copies/ml by bDNA assay, or > 50 copies/ml by Ultrasensitive PCR assay in the 6 months prior to screening visit (A single "blip" of HIV-1 viral load >75 copies but <400 copies by bDNA assay, or >50 copies but <400 copies by Ultrasensitive PCR assay in the six months prior to screening visit with at least one subsequent HIV-1 viral load below the limit of detection will be accepted.)
- Any previous known hypersensitivity to components of the study drug formulation.
- Weight < 40 kilograms.
- Patient requires or is anticipated to require any of the prohibited medications noted in the protocol.
- Acute therapy for serious illness (in the opinion of the investigator) within 14 days prior to study entry unless the subject has completed ≥ 7 days of therapy and is considered clinically stable by the investigator.
- Any condition which, in the opinion of the investigator, would compromise the subject's ability to participate in the study.
- Any active opportunistic infections or Centers for Disease Control and Prevention (CDC) Category C conditions (with the exception of stable cutaneous Kaposi's Sarcoma and wasting syndrome due to HIV infection).
- Any malignancy requiring chemotherapy.
- Subject has any of the following laboratory results at screening:
Hemoglobin < 8.0 gr/dl Absolute neutrophil count < 750 cells/ml Platelet count < 40,000 Creatinine > 2.0 or calculated creatinine clearance < 40 ml/min
- Female patient who is pregnant or breast-feeding, or expecting to conceive or donate eggs during the study. Male patient who is planning to impregnate or
provide sperm donation during the study.
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00529243
Locations Show More
United States, California Kaiser Anaheim Anaheim, California, United States, 92807 Kaiser Hayward Hayward, California, United States, 95454 Kaiser Los Angeles Los Angeles, California, United States, 90027 Kaiser West Los Angeles Los Angeles, California, United States, 90034 Kaiser Panorama City Panorama City, California, United States, 91402 Kaiser San Francisco San Francisco, California, United States, 94118 Kaiser Santa Clara Santa Clara, California, United States, 95051 Kaiser Santa Clarita Santa Clarita, California, United States, 91355
Sponsors and CollaboratorsKaiser Permanente
Merck Sharp & Dohme Corp.
Principal Investigator: William J Towner, MD Kaiser Permanente
Responsible Party: Kaiser Permanente ClinicalTrials.gov Identifier: NCT00529243 History of Changes Other Study ID Numbers: 4908 Study First Received: September 12, 2007 Last Updated: July 10, 2018
Keywords provided by Kaiser Permanente:Treatment Experience
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on October 15, 2019
This information is provided by ClinicalTrials.gov.